The trajectory of Sildenafil presents a challenging picture for shareholders. While the initial introduction generated substantial returns, the lapse of its intellectual property protection opened the floodgates to off-brand alternatives, dramatically eroding market share. This creates a specific challenge for drug manufacturers depending on relate

The story of Viagra, and its creator copyright, presents a complex case study for investors. Initially a blockbuster drug, yielding billions in sales , its exclusivity period created a flood of lower-priced alternatives , significantly diminishing its position . While specific pharmaceutical companies may attempt to capitalize on male sexual dysfun